medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2011; 10 (3)


Course of a HBsAg positive liver transplantation in a hepatitis B and D virus coinfected recipient

Bahde R, Hölzen JP, Wolters HH, Schmidt HHJ, Bock CT, Lügering A, Spieker T, Senninger N, Brockmann JG

Idioma: Ingles.
Referencias bibliográficas: 25
Paginas: 355-360
Archivo PDF: 204.43 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: A survery of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009; 15: 223-32.

  2. Gonzalez-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, Lau JY. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus- negative recipient. Transplantation 1994; 58: 114-16.

  3. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-8.

  4. Hwang SH, Lee SG, Park KM, Kim KH, Ahn CS, Oh HB, Moon DB, et al. Five-year follow-up of a hepatitis B virus-positive recipient of a hepatitis B surface antigen-positive living donor liver graft. Liver Transpl 2006; 12: 993-7.

  5. Soejima Y, Shimada M, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, Nakamuta M, et al. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int 2007; 27: 1282-6.

  6. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.

  7. Rizetto M. Hepatitis D: Clinical features and therapy. Dig Dis 2010; 28: 139-43.

  8. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39: S212–S19.

  9. Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Aricò S, Calzia R, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98: 437-41.

  10. Rifai K, Wedemeyer H, Rosenau J, Klempnauer J, Strassburg CP, Manns MP, Tillmann HL. Longer survival of liver transplant recipients with hepatits virus coinfections. Clin Transplant 2007; 21: 258-64.

  11. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Eng J Med 1993; 329: 1842-7.

  12. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi- Venon W, Alessandria C, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transplant 2005; 11: 402-9.

  13. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-S85.

  14. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF, Gigou M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-9.

  15. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-6.

  16. Smedile A, Casey JL, Cote PJ, Durazzo M, Lavezzo B, Purcell RH, Rizzetto M, et al. Hepatitis D viremia following or thotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology 1998; 27: 1723-9.

  17. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, Verran D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globuline. Liver Transpl Surg 1999; 5: 512-19.

  18. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.

  19. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005; 12: 2-9.

  20. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot- Peignoux M, Boyer N, Pham BN, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-35.

  21. Erhardt A, Gerlich W, Starke C Wend U, Donner A, Sagir A, Heintges T, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-10.

  22. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, et al. Long-term efficacy of tenofovir monotherapy for hepatits B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.

  23. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 2010 Sep 3 (Epub ahead of print).

  24. Mansour W, Ducancelle A, Le Gal F, Le Guillou-Guillemette H, Abgueguen P, Pivert A, Calès P, et al. Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 2010; 47: 97-9.

  25. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus (HDV). J Clin Invest 2003; 112: 407-14.




2020     |     www.medigraphic.com